Found 9 matching trials
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma N/A An open-label, single-arm, multicenter, prospective clinical study of Hanli...
Show More Location
Department of Oncology, The First Affiliated Hospital of Zhengzhou University
Learn More & Join Trial
Subcutaneous Cardiac Monitoring of Patients With BTK Inhibitors NA The goal of this clinical trial is to screen all types of electrocardiograp...
Show More Location
Caen University Hospital, Department of Pharmacology
Learn More & Join Trial
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors NA This study will enroll patients initiating Bruton Tyrosine Kinase (BTK) inh...
Show More Location
Northwell (Northshore University/Long Island Jewish Hospitals)
Learn More & Join Trial
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. PHASE4 BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform tri...
Show More Location
Copenhagen University Hospital - Rigshospitalet
Learn More & Join Trial
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) PHASE3 This study evaluated the safety, efficacy and clinical benefit of BGB-3111 ...
Show More Location
Mayo Clinic Phoenix
Learn More & Join Trial
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) N/A The goal of this observational study is to comprehensively profile six immu...
Show More Location
Radboud University Medical Center
Learn More & Join Trial
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma PHASE2 This phase II trial studies the effects of venetoclax and rituximab in comp...
Show More Location
Banner University Medical Center - Tucson
Learn More & Join Trial
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma PHASE3 Mantle cell lymphoma (MCL) is an aggressive yet often indolent type of B-ce...
Show More Location
Beijing Cancer hospital
Learn More & Join Trial
Current Status of BTKi Treatment for CLL/SLL in China N/A BTKi has become the standard treatment regimen for CLL/SLL,there is a lack ...
Show More Location
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Learn More & Join Trial